Related Experiment Video
Updated: Jun 28, 2025
08:24
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
2.2K
In silico study on graphene quantum dots modified with various functional groups inhibiting α‑synuclein dimerization.
Xiaoxiao Wu1, Gang Wang1, Ziqian Zhao1
1Key Laboratory of Exercise and Health Sciences (Ministry of Education), Shanghai Frontiers Science Research Base of Exercise and Metabolic Health, and School of Exercise and Health, Shanghai University of Sport, 399 Changhai Road, Shanghai 200438, China.
Journal of Colloid and Interface Science
|April 19, 2024
Summary
Graphene quantum dots (GQDs) inhibit alpha-synuclein dimerization, a key step in Parkinson's disease. Charged GQDs, particularly GQD-COO-, show the most promise for nanomedicines targeting amyloid aggregation.
Area of Science:
- Nanomaterials Science
- Neuroscience
- Computational Chemistry
Background:
- Parkinson's disease pathogenesis involves alpha-synuclein (αS) dimerization.
- Graphene quantum dots (GQDs) are explored for therapeutic potential.
Purpose of the Study:
- To investigate the inhibitory effects of various functionalized GQDs on αS dimerization.
- To understand the molecular mechanisms of GQD-αS interactions.
Main Methods:
- All-atom replica-exchange molecular dynamics simulations (75.6 μs).
- Analysis of conformation ensembles, binding behavior, and free energy.
- Studied αS non-amyloid component region with functionalized GQDs.
Main Results:
- All GQDs inhibited β-sheet and hydrogen bond formation in αS dimers.
- Charged GQDs impeded extended β-sheet growth.
- GQD binding disrupted αS inter-peptide interactions via π-π stacking, CH-π, and salt-bridge/hydrogen bonding (for charged GQDs).
Conclusions:
- Graphene quantum dots effectively inhibit αS dimerization and amyloid aggregation.
- GQD-COO- demonstrated optimal inhibitory effects, binding mode, and intensity.
- Functionalized GQDs show promise as nanomedicines for neurodegenerative diseases.
Keywords:
Graphene quantum dotsInhibitory mechanismMolecular dynamics simulationParkinson’s diseaseα-synuclein aggregation
